Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01 2021 - 5:00PM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, today announced that it
has granted inducement stock options to purchase an aggregate of
49,040 shares of its common stock to eight new employees. These
inducement stock options have a grant date of March 31, 2021, and
were granted as inducements material to the new employees entering
into employment with Biocept in accordance with Nasdaq Listing Rule
5635(c)(4).
The inducement stock options have an exercise price of $5.09 per
share, the closing price of Biocept’s common stock on March 31,
2021 (the grant date), are non-qualified stock options, have a
ten-year term and vest over four years, with 25% of the shares
vesting on the one-year anniversary of the vesting commencement
date and the remaining 75% of the shares vesting in equal monthly
installments over the following 36 months, subject to the new
employee’s continued service with Biocept through the applicable
vesting dates. The inducement stock options are subject to the
terms and conditions of Biocept’s Amended and Restated 2013 Equity
Incentive Plan.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept is developing and
commercializing its cerebrospinal fluid (CSF) assay that detects
cancer that has metastasized to the central nervous system. The
Company’s CSF assay identifies molecular targets for clinical
decision making and provides quantitative information for
monitoring treatment response. Biocept’s patented Target Selector™
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and
circulating tumor DNA (ctDNA) with higher sensitivity and
specificity than most commercial assays. Additionally, Biocept is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For additional information,
visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210401005905/en/
Investor Contact: LHA Investor Relations Jody Cain
Jcain@lhai.com 310-691-7100
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024